Legend Biotech Corporation
LEGNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeLegend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other. Valued at $3.75B, LEGN is a mid-cap name in its sector. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
Market Cap
$3.75B
Beta
0.57
P/E (TTM)
—
P/E (Fwd)
18.35
EPS (TTM)
$-0.52
EPS (Fwd)
$1.05
ROE
-8.1%
ROA
-1.9%
Cash
$964.6M
Total Debt
$278.2M
Free CF
$27.2M
52W Change
-40.0%
Annual Financials
Cash vs Debt
Where LEGN stands vs its 150-day and 200-day moving averages
As of the September 29, 2026 close, LEGN finished 19.67% below its 150-day moving average ($23.18) and 17.17% below its 200-day moving average ($22.48). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LEGN overbought or oversold?
At the September 29, 2026 close, LEGN's RSI(14) was 35.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $964.6M in cash and $278.2M in debt, LEGN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $27.2M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -8.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $68.8M (2021) to $1.03B (2025), reflecting a 1395% increase over the period.
LEGN's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LEGN.